<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211766</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006100</org_study_id>
    <secondary_id>NCI-2019-07435</secondary_id>
    <secondary_id>RG1006100</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>R21CA245456</secondary_id>
    <nct_id>NCT04211766</nct_id>
  </id_info>
  <brief_title>Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer</brief_title>
  <official_title>Diet and the Colonic Exfoliome: A Novel, Non-Invasive Approach to Testing Interventions in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how fiber and fish oil supplements affect the metabolism and activities of
      colon cells in healthy individuals. Diet is an important risk factor for colorectal cancer,
      and several dietary components important in colorectal cancer prevention are modified by gut
      microbial metabolism. Giving fiber and fish oil supplements may inhibit the growth of gut
      cells and ultimately reduce risk of colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are randomized to receive two dietary interventions in assigned random order.
      They either receive the dietary fiber supplement and fish oil supplement orally (PO) daily or
      they receive a fiber control and corn oil supplement daily for 30 days during the first
      intervention period. Then they enter a washout period for 60 days when they do not receive
      any treatment. After that they complete the second intervention period during which they
      receive the other intervention.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mRNA expression profiles in the exfoliome</measure>
    <time_frame>Baseline to 2 years</time_frame>
    <description>Poly A+ RNA will be isolated from exfoliated cells in stool, and libraries generated from stool RNA will be sequenced on an Illumina HiSeq 2500 platform.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a fiber supplement daily and a fish oil supplement PO daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a fiber supplement placebo daily and a fish oil supplement placebo daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Fiber</intervention_name>
    <description>Given fiber supplement</description>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <other_name>Fiber</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Given fish oil supplement</description>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <other_name>Oil, Fish</other_name>
    <other_name>Seafood Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given fiber supplement placebo</description>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given fish oil supplement placebo (corn oil)</description>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Normal-overweight (body mass index [BMI] of 18-30 kg/m^2)

          -  Women will be postmenopausal, with no menstrual period in 12 months

          -  Non-smoking

          -  Consume fiber intakes of less than &lt; 20 g/d

          -  White blood cell count 3,000-11,000/mm^3

          -  Platelet count 100,000-400,000 mm^3

          -  Hematocrit 33-50% (women); 36-50% (men)

          -  Bilirubin 0.2-1.3 mg/dL

          -  Aspartate aminotransferase (AST) 0-35 U/L

          -  Alanine aminotransferase (ALT) 0-40 U/L

          -  Alkaline phosphatase 20-125 U/L

          -  Creatinine =&lt; 1.2 mg/dL

          -  Potassium 3.5-5.0 mmol/L

        Exclusion Criteria:

          -  Chronic medical illness, history of gastrointestinal disorders (e.g., ulcerative
             colitis, Crohn disease, celiac sprue, hereditary nonpolyposis colorectal cancer
             [HNPCC], familial adenomatous polyposis, pancreatic disease, previous gastrointestinal
             resection, radiation or chemotherapy, and cancer (other than non-melanoma skin cancer)

          -  Weight change greater than 4.5 kg within past year

          -  Oral or intravenous (IV) antibiotic use within the past 3 months

          -  Regular use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)

          -  Smoking or use of cannabis products

          -  Known allergy to fish

          -  Intention to relocate out of study area within next 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Lampe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Lampe</last_name>
    <phone>206-667-6580</phone>
    <email>jlampe@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Texas A&amp;M</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77843</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Chapkin</last_name>
      <email>r-chapkin@tamu.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Chapkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Johanna Lampe</last_name>
      <phone>206-667-6580</phone>
      <email>jlampe@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Johanna Lampe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colon</keyword>
  <keyword>Rectum</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

